· Журналы · Книги · О проекте ·Электронные версии книг издательства “Атмосфера” поступили в продажу Издательство “Атмосфера” идет в ногу со временем и открывает на своем сайте раздел электронных версий своих книг. Теперь вы можете приобрести не только традиционную бумажную книгу в картонном переплете, но и .pdf-файл, снабженный гиперссылками на каждую главу издания. В электронной версии проще отыскать рисунок и таблицу. Чтобы обратиться к ним, достаточно нажать на ссылку на каждый из них. Исчезла зависимость от тиража – вы можете приобрести даже те бестселлеры, тираж которых уже разошелся, такие как “Саркоидоз” или “Заболевания органов дыхания при беременности”. Упростилось получение вами книг – в течение двух рабочих дней после оплаты требуемые файлы придут на ваш e-mail. Ну и наконец, цена – электронные версии наших книг гораздо дешевле, чем бумажные издания. Заказывайте электронные версии книг издательства “Атмосфера” на сайте, а также по телефону: (495) 730-63-51 и по e-mail: atm-press2012@yandex.ru ИНТЕРНЕТ-МАГАЗИН    Лечебное дело 2022 / N 3/4 Пожилой пациент с фибрилляцией предсердий: особенности терапии пероральными антикоагулянтами Ю.В. Котовская Список литературы/References 1. Virani SS, Alonso A, Aparicio HJ, Benjamin EJ, Bittencourt MS, Callaway CW, Carson AP, Chamberlain AM, Cheng S, Delling FN, Elkind MSV, Evenson KR, Ferguson JF, Gupta DK, Khan SS, Kissela BM, Knutson KL, Lee CD, Lewis TT, Liu J, Loop MS, Lutsey PL, Ma J, Mackey J, Martin SS, Matchar DB, Mussolino ME, Navaneethan SD, Perak AM, Roth GA, Samad Z, Satou GM, Schroeder EB, Shah SH, Shay CM, Stokes A, VanWagner LB, Wang NY, Tsao CW; American Heart Association Council on Epidemiology and Prevention Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics – 2021 update: a report from the American Heart Association. Circulation. 2021;143(8):e254-e743. 2. Воробьева Н.М., Ткачева О.Н., Котовская Ю.В., Овчарова Л.Н., Селезнева Е.В. Российское эпидемиологическое исследование ЭВКАЛИПТ: протокол и базовые характеристики участников. Российский журнал гериатрической медицины. 2021;1:35-43. [Vorobyeva NM, Tkacheva ON, Kotovskaya YuV, Ovcharova LN, Selezneva EV. Russian epidemiological study EVKALIPT: protocol and basic characteristics of participants. Russian Journal of Geriatric Medicine. 2021;1:35-43. (In Russ.).] DOI: 10.37586/2686-8636-1-2021-35-43 3. Liao JN, Chan YH, Kuo L, Tsai CT, Lim SS, Chao TF. Optimal anticoagulation in elderly patients with atrial fibrillation: which drug at which dose? Kardiologia Polska. 2022;80(2):128-136. DOI: 10.33963/KP.a2022.0046 4. Российское кардиологическое общество; Всероссийское научное общество специалистов по клинической электрофизиологии, аритмологии и кардиостимуляции; Ассоциация сердечно-сосудистых хирургов России. Клинические рекомендации. Фибрилляция и трепетание предсердий у взрослых. Кодирование по Международной статистической классификации болезней и проблем, связанных со здоровьем: I48.0/I48.1/I48.2/I48.3/I48.4/I48.9. Год утверждения (частота пересмотра): 2020. Возрастная категория: взрослые. М., 2020. 185 с. Ссылка активна на 19.12.2022. [Russian Society of Cardiology; All-Russian Scientific Society of Specialists in Clinical Electrophysiology, Arrhythmology, and Pacing; Russian Association of Cardio-Vascular Surgeons. Clinical recommendations. Fibrillation and atrial flutter in adults. ICD: I48.0/I48.1/I48.2/I48.3/I48.4/I48.9. Year of approval (frequency of revision): 2020. Age category: adults. Moscow, 2020. 185 p. (In Russ.).] https://cr.minzdrav.gov.ru/recomend/382_1 5. Orlandi M, Dover DC, Sandhu RK, Hawkins NM, Kaul P, McAlister FA. The introduction of direct oral anticoagulants has not resolved treatment gaps for frail patients with nonvalvular atrial fibrillation. The Canadian Journal of Cardiology. 2022;38(1):77-84. DOI: 10.1016/j.cjca.2021.09.021 6. Soliman EZ, Rahman AF, Zhang ZM, Rodriguez CJ, Chang TI, Bates JT, Ghazi L, Blackshear JL, Chonchol M, Fine LJ, Ambrosius WT, Lewis CE. Effect of intensive blood pressure lowering on the risk of atrial fibrillation. Hypertension (Dallas, Tex.: 1979). 2020;75(6):1491-1496. DOI: 10.1161/HYPERTENSIONAHA.120.14766 7. Middeldorp ME, Pathak RK, Meredith M, Mehta AB, Elliott AD, Mahajan R, Twomey D, Gallagher C, Hendriks JML, Linz D, McEvoy RD, Abhayaratna WP, Kalman JM, Lau DH, Sanders P. PREVEntion and regReSsive Effect of weight-loss and risk factor modification on Atrial Fibrillation: the REVERSE-AF study. Europace. 2018;20(12):1929-1935. DOI: 10.1093/europace/euy117 8. Abed HS, Wittert GA, Leong DP, Shirazi MG, Bahrami B, Middeldorp ME, Lorimer MF, Lau DH, Antic NA, Brooks AG, Abhayaratna WP, Kalman JM, Sanders P. Effect of weight reduction and cardiometabolic risk factor management on symptom burden and severity in patients with atrial fibrillation: a randomized clinical trial. JAMA. 2013;310(19):2050-2060. DOI: 10.1001/jama.2013.280521 9. Health Research Authority. LOSE-AF: can weight loss help patients with atrial fibrillation? (LOSE-AF). Accessed 2022 Dec 19. https://ClinicalTrials.gov/show/NCT03713775 10. Ткачева О.Н., Котовская Ю.В., Рунихина Н.К., Фролова Е.В., Наумов А.В., Воробьева Н.М., Остапенко В.С., Мхитарян Э.А., Шарашкина Н.В., Тюхменев Е.А., Переверзев А.П., Дудинская Е.Н. Клинические рекомендации «Старческая анемия». Часть 2. Российский журнал гериатрической медицины. 2020;2:115-130. [Tkacheva ON, Kotovskaya YuV, Runikhina NK, Frolova EV, Naumov AV, Vorobyeva NM, Ostapenko VS, Mkhitaryan EA, Sharashkina NV, Tyukhmenev EA, Pereverzev AP, Dudinskaya EN. Clinical guidelines. Frailty. Part 2. Russian Journal of Geriatric Medicine. 2020;2:115-130. (In Russ.).] DOI: 10.37586/2686-8636-2-2020-115-130 11. Voskoboinik A, Kalman JM, De Silva A, Nicholls T, Costello B, Nanayakkara S, Prabhu S, Stub D, Azzopardi S, Vizi D, Wong G, Nalliah C, Sugumar H, Wong M, Kotschet E, Kaye D, Taylor AJ, Kistler PM. Alcohol abstinence in drinkers with atrial fibrillation. The New England Journal of Medicine. 2020;382(1):20-28. DOI: 10.1056/NEJMoa1817591 12. Lee SR, Choi EK, Jung JH, Han KD, Oh S, Lip GYH. Lower risk of stroke after alcohol abstinence in patients with incident atrial fibrillation: a nationwide population-based cohort study. European Heart Journal. 2021;42(46):4759-4768. DOI: 10.1093/eurheartj/ehab315 13. Holmqvist F, Guan N, Zhu Z, Kowey PR, Allen LA, Fonarow GC, Hylek EM, Mahaffey KW, Freeman JV, Chang P, Holmes DN, Peterson ED, Piccini JP, Gersh BJ; ORBIT-AF Investigators. Impact of obstructive sleep apnea and continuous positive airway pressure therapy on outcomes in patients with atrial fibrillation – results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF). American Heart Journal. 2015;169(5): 647-654.e2. DOI: 10.1016/j.ahj.2014.12.024 14. Seyed Ahmadi S, Svensson AM, Pivodic A, Rosengren A, Lind M. Risk of atrial fibrillation in persons with type 2 diabetes and the excess risk in relation to glycaemic control and renal function: a Swedish cohort study. Cardiovascular Diabetology. 2020;19(1):9. DOI: 10.1186/s12933-019-0983-1 15. Mozaffarian D, Furberg CD, Psaty BM, Siscovick D. Physical activity and incidence of atrial fibrillation in older adults: the cardiovascular health study. Circulation. 2008;118(8):800-807. DOI: 10.1161/CIRCULATIONAHA.108.785626 16. Proietti M, Boriani G, Laroche C, Diemberger I, Popescu MI, Rasmussen LH, Sinagra G, Dan GA, Maggioni AP, Tavazzi L, Lane DA, Lip GYH; EORP-AF General Pilot Registry Investigators. Self-reported physical activity and major adverse events in patients with atrial fibrillation: a report from the EURObservational Research Programme Pilot Survey on Atrial Fibrillation (EORP-AF) General Registry. Europace. 2017;19(4):535-543. DOI: 10.1093/europace/euw150 17. Svendsen JH, Diederichsen SZ, Højberg S, Krieger DW, Graff C, Kronborg C, Olesen MS, Nielsen JB, Holst AG, Brandes A, Haugan KJ, Køber L. Implantable loop recorder detection of atrial fibrillation to prevent stroke (the LOOP study): a randomised controlled trial. The Lancet. 2021;398(10310):1507-1516. DOI: 10.1016/S0140-6736(21)01698-6 18. Tulner LR, Kuper IM, van Campen JP, Mac Gillavry MR, Kwa VI, Koks CH, Beijnen JH, Brandjes DP. Contraindications for anticoagulation in older patients with atrial fibrillation: a narrative review. Current Drug Safety. 2010;5(3):223-233. DOI: 10.2174/157488610791698253 19. Ekerstad N, Karlsson T, Söderqvist S, Karlson BW. Hospitalized frail elderly patients – atrial fibrillation, anticoagulation and 12 months’ outcomes. Clinical Interventions in Aging. 2018;13:749-756. DOI: 10.2147/CIA.S159373 20. Piccini JP, Hammill BG, Sinner MF, Hernandez AF, Walkey AJ, Benjamin EJ, Curtis LH, Heckbert SR. Clinical course of atrial fibrillation in older adults: the importance of cardiovascular events beyond stroke. European Heart Journal. 2014;35(4):250-256. DOI: 10.1093/eurheartj/eht483 21. Ouellet GM, Fried TR, Gilstrap LG, O’Leary JR, Austin AM, Skinner JS, Cohen AB. Anticoagulant use for atrial fibrillation among persons with advanced dementia at the end of life. JAMA Internal Medicine. 2021;181(8):1121-1123. DOI: 10.1001/jamainternmed.2021.1819 22. Ruff CT, Giugliano RP, Braunwald E, Hoffman EB, Deenadayalu N, Ezekowitz MD, Camm AJ, Weitz JI, Lewis BS, Parkhomenko A, Yamashita T, Antman EM. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. The Lancet. 2014;383(9921):955-962. DOI: 10.1016/S0140-6736(13)62343-0 23. Alcusky M, Tjia J, McManus DD, Hume AL, Fisher M, Lapane KL. Comparative safety and effectiveness of direct-acting oral anticoagulants versus warfarin: a national cohort study of nursing home residents. Journal of the General Internal Medicine. 2020;35(8):2329-2337. DOI: 10.1007/s11606-020-05777-3 24. Amin A, Garcia Reeves AB, Li X, Dhamane A, Luo X, Di Fusco M, Nadkarni A, Friend K, Rosenblatt L, Mardekian J, Pan X, Yuce H, Keshishian A. Effectiveness and safety of oral anticoagulants in older adults with non-valvular atrial fibrillation and heart failure. PLoS One. 2019;14(3):e0213614. DOI: 10.1371/journal.pone.0213614 25. Malik AH, Yandrapalli S, Aronow WS, Panza JA, Cooper HA. Meta-analysis of direct-acting oral anticoagulants compared with warfarin in patients >75 years of age. The American Journal of Cardiology. 2019;123(12):2051-2057. DOI: 10.1016/j.amjcard.2019.02.060 26. Wong JM, Maddox TM, Kennedy K, Shaw RE. Comparing major bleeding risk in outpatients with atrial fibrillation or flutter by oral anticoagulant type (from the National Cardiovascular Disease Registry’s Practice Innovation and Clinical Excellence Registry). The American Journal of Cardiology. 2020;125(10):1500-1507. DOI: 10.1016/j.amjcard.2020.02.028 27. Lau WCY, Cheung CL, Man KKC, Chan EW, Sing CW, Lip GYH, Siu CW, Lam JKY, Lee ACH, Wong ICK. Association between treatment with apixaban, dabigatran, rivaroxaban, or warfarin and risk for osteoporotic fractures among patients with atrial fibrillation: a population-based cohort study. Annals of Internal Medicine. 2020;173(1):1-9. DOI: 10.7326/M19-3671 28. Kim DH, Pawar A, Gagne JJ, Bessette LG, Lee H, Glynn RJ, Schneeweiss S. Frailty and clinical outcomes of direct oral anticoagulants versus warfarin in older adults with atrial fibrillation: a cohort study. Annals of Internal Medicine. 2021;174(9):1214-1223. DOI: 10.7326/M20-7141 29. Dalgaard F, Xu H, Matsouaka RA, Russo AM, Curtis AB, Rasmussen PV, Ruwald MH, Fonarow GC, Lowenstern A, Hansen ML, Pallisgaard JL, Alexander KP, Alexander JH, Lopes RD, Granger CB, Lewis WR, Piccini JP, Al-Khatib SM. Management of atrial fibrillation in older patients by morbidity burden: insights from get with the guidelines – atrial fibrillation. Journal or the American Heart Association. 2020;9(23):e017024. DOI: 10.1161/JAHA.120.017024 30. Martinez BK, Sood NA, Bunz TJ, Coleman CI. Effectiveness and safety of apixaban, dabigatran, and rivaroxaban versus warfarin in frail patients with nonvalvular atrial fibrillation. Journal of the American Heart Association. 2018;7(8):e008643. DOI: 10.1161/JAHA.118.008643 31. Rao MP, Vinereanu D, Wojdyla DM, Alexander JH, Atar D, Hylek EM, Hanna M, Wallentin L, Lopes RD, Gersh BJ, Granger CB; Apixaban for Reduction in Stroke Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) Investigators. Clinical outcomes and history of fall in patients with atrial fibrillation treated with oral anticoagulation: insights from the ARISTOTLE trial. The American Journal of Medicine. 2018;131(3):269-275.e2. DOI: 10.1016/j.amjmed.2017.10.036 32. Steffel J, Giugliano RP, Braunwald E, Murphy SA, Mercuri M, Choi Y, Aylward P, White H, Zamorano JL, Antman EM, Ruff CT. Edoxaban versus warfarin in atrial fibrillation patients at risk of falling: ENGAGE AF-TIMI 48 Analysis. Journal of the American College of Cardiology. 2016;68(11):1169-1178. DOI: 10.1016/j.jacc.2016.06.034 33. Wei W, Rasu RS, Hernández-Muñoz JJ, Flores RJ, Rianon NJ, Hernández-Vizcarrondo GA, Brown AT. Impact of fall risk and direct oral anticoagulant treatment on quality-adjusted life-years in older adults with atrial fibrillation: a Markov Decision Analysis. Drugs & Aging. 2021;38(8):713-723. DOI: 10.1007/s40266-021-00870-6 34. Kim D, Yang PS, Yu HT, Kim TH, Jang E, Sung JH, Pak HN, Lee MY, Lee MH, Lip GYH, Joung B. Risk of dementia in stroke-free patients diagnosed with atrial fibrillation: data from a population-based cohort. European Heart Journal. 2019;40(28):2313-2323. DOI: 10.1093/eurheartj/ehz386 35. Ding M, Fratiglioni L, Johnell K, Santoni G, Fastbom J, Ljungman P, Marengoni A, Qiu C. Atrial fibrillation, antithrombotic treatment, and cognitive aging: a population-based study. Neurology. 2018;91(19):e1732-e1740. DOI: 10.1212/WNL.0000000000006456 36. Lee SR, Choi EK, Park SH, Jung JH, Han KD, Oh S, Lip GYH. Comparing warfarin and 4 direct oral anticoagulants for the risk of dementia in patients with atrial fibrillation. Stroke. 2021;52(11):3459-3468. DOI: 10.1161/STROKEAHA.120.033338 37. Alexander KP, Brouwer MA, Mulder H, Vinereanu D, Lopes RD, Proietti M, Al-Khatib SM, Hijazi Z, Halvorsen S, Hylek EM, Verheugt FWA, Alexander JH, Wallentin L, Granger CB; ARISTOTLE Investigators. Outcomes of apixaban versus warfarin in patients with atrial fibrillation and multi-morbidity: insights from the ARISTOTLE trial. American Heart Journal. 2019;208:123-131. DOI: 10.1016/j.ahj.2018.09.017 38. Jaspers Focks J, Brouwer MA, Wojdyla DM, Thomas L, Lopes RD, Washam JB, Lanas F, Xavier D, Husted S, Wallentin L, Alexander JH, Granger CB, Verheugt FW. Polypharmacy and effects of apixaban versus warfarin in patients with atrial fibrillation: post hoc analysis of the ARISTOTLE trial. BMJ. 2016;353:i2868. DOI: 10.1136/bmj.i2868 39. Wehling M. How to use the FORTA (“Fit fOR The Aged”). List to improve pharmacotherapy in the elderly. Drug Research (Stuttgart). 2016;66(2):57-62. DOI: 10.1055/s-0035-1549935 40. Pazan F, Collins R, Gil VM, Hanon O, Hardt R, Hoffmeister M, Monteiro P, Quinn TJ, Ropers D, Sergi G, Verheugt FWA, Wehling M. A structured literature review and international consensus validation of FORTA labels of Oral Anticoagulants for Long-Term Treatment of Atrial Fibrillation in Older Patients (OAC-FORTA 2019). Drugs & Aging. 2020;37(7):539-548. DOI: 10.1007/s40266 020-00771-0 41. Deshpande CG, Kogut S, Willey C. Real-world health care costs based on medication adherence and risk of stroke and bleeding in patients treated with novel anticoagulant therapy. Journal of Managed Care & Specialty Pharmacy. 2018;24:430-439. DOI: 10.18553/jmcp.2018.24.5.430 42. Ozaki AF, Choi AS, Le QT, Ko DT, Han JK, Park SS, Jackevicius CA. Real-world adherence and persistence to direct oral anticoagulants in patients with atrial fibrillation: a systematic review and meta-analysis. Circulation. Cardiovascular Quality and Outcomes. 2020;13(3):e005969. DOI: 10.1161/CIRCOUTCOMES.119.005969 43. Lee MY, Han S, Bang OY, On YK, Jang SW, Han S, Ryu J, Park YJ, Kang S, Suh HS, Kim YH. Drug utilization pattern of oral anticoagulants in patients with atrial fibrillation: a nationwide population-based study in Korea. Advances in Therapy. 2022;39(7):3112-3130. DOI: 10.1007/s12325-022-02151-z 44. Ткачева О.Н., Воробьева Н.М., Котовская Ю.В., Рунихина Н.К., Стражеско И.Д., Виллевальде С.В., Драпкина О.М., Комаров А.Л., Орлова Я.А., Панченко Е.П., Погосова Н.В., Фролова Е.В., Явелов И.С., Аверков О.В., Архипов М.В., Баранова Е.И., Барбараш О.Л., Бойцов С.А., Болотнова Т.В., Булгакова С.В. Галявич А.С., Глезер М.Г., Гринштейн Ю.И., Дупляков Д.В., Зенин С.А., Ильницкий А.Н., Кириллов О.В., Кобалава Ж.Д., Козиолова Н.А., Конради А.О., Напалков Д.А., Новикова Н.А., Павлова Т.В., Прощаев К.И., Терещенко С.Н., Фомин И.В., Чесникова А.И., Якушин С.С. Антитромботическая терапия в пожилом и старческом возрасте: согласованное мнение экспертов Российской ассоциации геронтологов и гериатров и Национального общества профилактической кардиологии. Кардиоваскулярная терапия и профилактика. 2021;20(3):2847. [Tkacheva ON, Vorobyeva NM, Kotovskaya YuV, Runikhina NK, Strazhesco ID, Villevalde SV, Drapkina OM, Komarov AL, Orlova YaA, Panchenko EP, Pogosova NV, Frolova EV, Yavelov IS, Averkov OV, Arkhipov MV, Baranova EI, Barbarash OL, Boytsov SA, Bolotnova TV, Bulgakova SV, Galyavich AS, Glezer MG, Grinstein YuI, Duplyakov DV, Zenin SA, Ilnitskiy AN, Kirillov OV, Kobalava ZhD, Koziolova NA, Konradi AO, Napalkov DA, Novikova NA, Pavlova TV, Proschayev KI, Tereshchenko SN, Fomin IV, Chesnikova AI, Yakushin SS. Antithrombotic therapy in the elderly and senile age: the consensus opinion of experts of the Russian Association of Gerontologists and Geriatricians and the National Society of Preventive Cardiology. Cardiovascular Therapy and Prevention. 2021;20(3):2847. (In Russ.).] DOI: 10.15829/1728-8800-2021-2847    [ Содержание выпуска N 3/4 | Выпуски журнала | Список журналов ]